Loss of S1P Lyase Expression in Human Podocytes Causes a Reduction in Nephrin Expression That Involves PKCδ Activation

Sphingosine 1-phosphate (S1P) lyase (SPL, Sgpl1) is an ER-associated enzyme that irreversibly degrades the bioactive lipid, S1P, and thereby regulates multiple cellular functions attributed to S1P. Biallelic mutations in the human Sglp1 gene lead to a severe form of a particular steroid-resistant nephrotic syndrome, suggesting that the SPL is critically involved in maintaining the glomerular ultrafiltration barrier, which is mainly built by glomerular podocytes. In this study, we have investigated the molecular effects of SPL knockdown (kd) in human podocytes to better understand the mechanism underlying nephrotic syndrome in patients. A stable SPL-kd cell line of human podocytes was generated by the lentiviral shRNA transduction method and was characterized for reduced SPL mRNA and protein levels and increased S1P levels. This cell line was further studied for changes in those podocyte-specific proteins that are known to regulate the ultrafiltration barrier. We show here that SPL-kd leads to the downregulation of the nephrin protein and mRNA expression, as well as the Wilms tumor suppressor gene 1 (WT1), which is a key transcription factor regulating nephrin expression. Mechanistically, SPL-kd resulted in increased total cellular protein kinase C (PKC) activity, while the stable downregulation of PKCδ revealed increased nephrin expression. Furthermore, the pro-inflammatory cytokine, interleukin 6 (IL-6), also reduced WT1 and nephrin expression. In addition, IL-6 caused increased PKCδ Thr505 phosphorylation, suggesting enzyme activation. Altogether, these data demonstrate that nephrin is a critical factor downregulated by the loss of SPL, which may directly cause podocyte foot process effacement as observed in mice and humans, leading to albuminuria, a hallmark of nephrotic syndrome. Furthermore, our in vitro data suggest that PKCδ could represent a new possible pharmacological target for the treatment of a nephrotic syndrome induced by SPL mutations.

[1]  O. Ichii,et al.  Membranous Nephropathy Associated With Multicentric Castleman Disease—Efficacy of Interleukin 6 Antibody for Nephrotic Syndrome , 2021, JCR: Journal of Clinical Rheumatology.

[2]  F. Schumacher,et al.  Mouse Liver Compensates Loss of Sgpl1 by Secretion of Sphingolipids into Blood and Bile , 2021, International journal of molecular sciences.

[3]  H. Stark,et al.  ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo , 2021, Molecules.

[4]  Lihua Wang,et al.  Dimethylamine enhances platelet hyperactivity in chronic kidney disease model , 2021, Journal of Bioenergetics and Biomembranes.

[5]  J. Casanova,et al.  Impaired respiratory burst contributes to infections in PKCδ-deficient patients , 2021, The Journal of experimental medicine.

[6]  J. Pfeilschifter,et al.  Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. , 2021, Matrix biology : journal of the International Society for Matrix Biology.

[7]  M. Franco-Molina,et al.  The Inflammatory Process Modulates the Expression and Localization of WT1 in Podocytes Leading to Kidney Damage , 2021, In Vivo.

[8]  G. Remuzzi,et al.  Podocytopathies , 2020, Nature Reviews Disease Primers.

[9]  Z. Dong,et al.  Protein Kinase C-δ Mediates Kidney Tubular Injury in Cold Storage-Associated Kidney Transplantation. , 2020, Journal of the American Society of Nephrology : JASN.

[10]  E. Gulbins,et al.  Podocytopathy and Nephrotic Syndrome in Mice with Podocyte-Specific Deletion of the Asah1 Gene: Role of Ceramide Accumulation in Glomeruli. , 2020, The American journal of pathology.

[11]  J. Pfeilschifter,et al.  Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge , 2020, International journal of molecular sciences.

[12]  Bisera Stepanovska,et al.  Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. , 2020, Pharmacological research.

[13]  J. Saba Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease[S] , 2019, Journal of Lipid Research.

[14]  A. Newton,et al.  Activation of atypical protein kinase C by sphingosine 1-phosphate revealed by an aPKC-specific activity reporter , 2019, Science Signaling.

[15]  Hui Tang,et al.  IL‐6 increases podocyte motility via MLC‐mediated focal adhesion impairment and cytoskeleton disassembly , 2018, Journal of cellular physiology.

[16]  J. Pfeilschifter,et al.  Sphingolipid signaling in renal fibrosis. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[17]  N. Jones,et al.  Nephrin Signaling in the Podocyte: An Updated View of Signal Regulation at the Slit Diaphragm and Beyond , 2018, Front. Endocrinol..

[18]  P. Garg A Review of Podocyte Biology , 2018, American Journal of Nephrology.

[19]  A. Newton Protein kinase C: perfectly balanced , 2018, Critical reviews in biochemistry and molecular biology.

[20]  Pitter F. Huesgen,et al.  N-Degradomic Analysis Reveals a Proteolytic Network Processing the Podocyte Cytoskeleton. , 2017, Journal of the American Society of Nephrology : JASN.

[21]  E. McGowan,et al.  “Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer , 2017, International journal of molecular sciences.

[22]  Chun Zhang,et al.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update , 2017, Front. Immunol..

[23]  Y. Frishberg,et al.  Deficiency of the sphingosine‐1‐phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications , 2017, Human mutation.

[24]  K. Schwarz,et al.  Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency , 2017, The Journal of clinical investigation.

[25]  L. Metherell,et al.  Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome , 2017, The Journal of clinical investigation.

[26]  W. Nickel,et al.  Sphingosine-1-Phosphate Lyase Deficient Cells as a Tool to Study Protein Lipid Interactions , 2016, PloS one.

[27]  Hyunju Kim,et al.  Protein Kinase C Isoforms Differentially Regulate Hypoxia‐Inducible Factor‐1α Accumulation in Cancer Cells , 2016, Journal of cellular biochemistry.

[28]  Friedhelm Hildebrandt,et al.  Exploring the genetic basis of early-onset chronic kidney disease , 2016, Nature Reviews Nephrology.

[29]  Hyung Gyun Kim,et al.  Endosulfan Induces CYP1A1 Expression Mediated through Aryl Hydrocarbon Receptor Signal Transduction by Protein Kinase C , 2015, Toxicological research.

[30]  S. Côté,et al.  Reduced Activity of Sphingosine-1-Phosphate Lyase Induces Podocyte-related Glomerular Proteinuria, Skin Irritation, and Platelet Activation , 2015, Toxicologic pathology.

[31]  A. Newton,et al.  Tuning the signalling output of protein kinase C. , 2014, Biochemical Society transactions.

[32]  J. Kopp,et al.  Podocyte Injury Caused by Indoxyl Sulfate, a Uremic Toxin and Aryl-Hydrocarbon Receptor Ligand , 2014, PloS one.

[33]  S. Spiegel,et al.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8 , 2014, British journal of pharmacology.

[34]  T. Hla,et al.  An update on the biology of sphingosine 1-phosphate receptors , 2014, Journal of Lipid Research.

[35]  P. Boor,et al.  Gp130-dependent signaling in the podocyte. , 2014, American journal of physiology. Renal physiology.

[36]  G. King,et al.  Glomerular VEGF resistance induced by PKCδ/SHP‐1 activation and contribution to diabetic nephropathy , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Sarah Spiegel,et al.  Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.

[38]  M. Grütter,et al.  PLP‐dependent enzymes as entry and exit gates of sphingolipid metabolism , 2011, Protein science : a publication of the Protein Society.

[39]  K. Ramos,et al.  AHR Regulates WT1 Genetic Programming during Murine Nephrogenesis , 2011, Molecular medicine.

[40]  R. Proia,et al.  Sphingosine-1-phosphate Lyase Deficiency Produces a Pro-inflammatory Response While Impairing Neutrophil Trafficking* , 2010, The Journal of Biological Chemistry.

[41]  G. Dong,et al.  PKC-delta promotes renal tubular cell apoptosis associated with proteinuria. , 2010, Journal of the American Society of Nephrology : JASN.

[42]  H. Haller,et al.  Podocytic PKC-Alpha Is Regulated in Murine and Human Diabetes and Mediates Nephrin Endocytosis , 2010, PloS one.

[43]  R. Proia,et al.  Sphingosine 1-Phosphate Lyase Deficiency Disrupts Lipid Homeostasis in Liver* , 2010, The Journal of Biological Chemistry.

[44]  J. Pfeilschifter,et al.  New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. , 2008, Biochemical pharmacology.

[45]  K. Tryggvason,et al.  Nephrin--a unique structural and signaling protein of the kidney filter. , 2007, Trends in molecular medicine.

[46]  M. ter Braak,et al.  Regulation and functional roles of sphingosine kinases , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[47]  C. S. Raymond,et al.  PDGF signaling specificity is mediated through multiple immediate early genes , 2007, Nature Genetics.

[48]  G. Geisslinger,et al.  LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. , 2006, Prostaglandins & other lipid mediators.

[49]  H. Haller,et al.  Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. , 2006, Kidney international.

[50]  H. Scholz,et al.  Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. , 2006, Blood.

[51]  J. Pfeilschifter,et al.  PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. , 2005, Biochemical and biophysical research communications.

[52]  K. Wagner,et al.  The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. , 2004, Journal of the American Society of Nephrology : JASN.

[53]  D. Mihálik,et al.  Nephrin expression is increased in anti-Thy1.1-induced glomerulonephritis in rats. , 2004, Biochemical and biophysical research communications.

[54]  J. Licht,et al.  WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. , 2004, Journal of the American Society of Nephrology : JASN.

[55]  Peter J Parker,et al.  PKC at a glance , 2004, Journal of Cell Science.

[56]  A. Hamaguchi,et al.  Sphingosine-dependent Protein Kinase-1, Directed to 14-3-3, Is Identified as the Kinase Domain of Protein Kinase Cδ* , 2003, Journal of Biological Chemistry.

[57]  K. Wagner,et al.  Oxygen‐regulated expression of the Wilms’ tumor suppressor Wt1 involves hypoxia‐inducible factor‐1 (HIF‐1) , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  P. Stenvinkel,et al.  Update on interleukin-6 and its role in chronic renal failure. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  Matthias Kretzler,et al.  Cell biology of the glomerular podocyte. , 2003, Physiological reviews.

[60]  M. O'hare,et al.  A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. , 2002, Journal of the American Society of Nephrology : JASN.

[61]  Angeliki Kotsianti,et al.  WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin , 2001, Current Biology.

[62]  L. Dekker,et al.  Sequential Activation of Rac-1, SEK-1/MKK-4, and Protein Kinase Cδ Is Required for Interleukin-6-induced STAT3 Ser-727 Phosphorylation and Transactivation* , 2001, The Journal of Biological Chemistry.

[63]  M. Waterfield,et al.  Beta1-integrin and PTEN control the phosphorylation of protein kinase C. , 2000, The Biochemical journal.

[64]  L. Holzman,et al.  Cloning and expression of the rat nephrin homolog. , 1999, The American journal of pathology.

[65]  Tong Zhang,et al.  Protein Kinase C δ Associates with and Phosphorylates Stat3 in an Interleukin-6-dependent Manner* , 1999, The Journal of Biological Chemistry.

[66]  A. Gurney,et al.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. , 1996, The EMBO journal.

[67]  S. Hewitt,et al.  Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. , 1994, The Journal of biological chemistry.

[68]  C. Wanner,et al.  Effect of nucleotides on the cytosolic free calcium activity and inositol phosphate formation in human glomerular epithelial cells , 1992, British journal of pharmacology.

[69]  Y. Hannun,et al.  Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds. , 1989, Biochemistry.